Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830543 · ClinicalTrials.gov registry record · Phase 3
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
A Phase 3 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,124
- Enrollment target
NCT01830543 is a Phase 3 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 2,124 participants.
The verdict
NCT01830543, a Phase 3 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,124 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).
Interventions
- DRUG rivaroxaban 2.5 mg
- DRUG rivaroxaban 15 mg
- DRUG rivaroxaban 10 mg
- DRUG aspirin (ASA)
- DRUG vitamin K antagonist (VKA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,124 participants |
| Start Date | 2013-05-10 |
| Est. Completion | 2016-07-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01830543
The ClinicalTrials.gov registry entry for NCT01830543 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rivaroxaban 2.5 mg is the first listed.
NCT01830543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01830543 about?
NCT01830543 is a clinical study titled "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention". The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT) or low-dose aspirin (ASA) or clopidogrel (or prasugrel or ticagrelor).
What is the current status of trial NCT01830543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,124 participants. The study started on 2013-05-10. Estimated completion is 2016-07-28.
What interventions are being tested in trial NCT01830543?
The interventions under investigation include: rivaroxaban 2.5 mg (DRUG), rivaroxaban 15 mg (DRUG), rivaroxaban 10 mg (DRUG), aspirin (ASA) (DRUG), vitamin K antagonist (VKA) (DRUG).
Who is sponsoring clinical trial NCT01830543?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.